Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alterity Therapeutics ( (AU:ATH) ) has issued an announcement.
Alterity Therapeutics has reported promising results from its ATH434 trials, indicating a strengthened efficacy signal at high doses and a potential market opportunity of USD $2.4 billion in MSA treatment. The company is actively engaging with the FDA to advance ATH434 to Phase 3 trials, with a cash balance of A$54.56M as of September 2025, underscoring its commitment to developing a first-in-class therapy for MSA.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, with a particular emphasis on Multiple System Atrophy (MSA).
YTD Price Performance: 10.0%
Average Trading Volume: 10,503,379
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$119.6M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.